NYSE: TMOThermo Fisher Scientific Inc Stock Forecast, Predictions & Price Target
Analyst price target for TMO
Based on 13 analysts offering 12 month price targets for Thermo Fisher Scientific Inc.
Min Forecast
$340.00-26.29%
Avg Forecast
$449.54-2.55%
Max Forecast
$494.00+7.09%
Should I buy or sell TMO stock?
Strong Buy
Strong Buy
11 analysts 73.33%
Buy
2 analysts 13.33%
Hold
2 analysts 13.33%
Sell
0 analysts 0.00%
Strong Sell
0 analysts 0.00%
Forecast return on equity
Is TMO forecast to generate an efficient return?
Company
24.70%
Industry
26.13%
Market
14.09%
TMO's Return on Equity is forecast to be high in 3 years (24.70%); analysts are confident in the firm's ability to efficiently generate return on equity
Forecast
Forecast return on assets
Is TMO forecast to generate an efficient return on assets?
Company
11.98%
Industry
10.03%
Market
10.00%
TMO is forecast to generate higher Return on Assets (11.98%) than the US Diagnostics & Research industry average (10.03%)
Forecast
TMO earnings per share forecast
What is TMO's earnings per share in the next 3 years based on estimates from 9 analysts?
Avg 1 year Forecast
$15.99+71.79%
Avg 2 year Forecast
$17.58+88.81%
Avg 3 year Forecast
$18.68+100.68%
TMO's earnings are forecast to grow at an exceptional rate of 36.94% per year
Forecast
TMO revenue forecast
What is TMO's revenue in the next 3 years based on estimates from 6 analysts?
Avg 1 year Forecast
$29.1B+11.01%
Avg 2 year Forecast
$31.0B+18.06%
Avg 3 year Forecast
$32.0B+21.94%
TMO's revenue is forecast to grow at a rate of 8.24% per year, which is not exceptional
Forecast
TMO earnings growth forecast
How is TMO forecast to perform vs Diagnostics & Research companies and vs the US market?
Company
36.94%
Industry
32.45%
Market
15.20%
TMO's earnings are forecast to grow faster (36.94% per year) than the US Diagnostics & Research industry average (32.45%)
Forecast
TMO's earnings are forecast to grow faster (36.94% per year) than the US market average (15.20%)
Forecast
TMO revenue growth forecast
How is TMO forecast to perform vs Diagnostics & Research companies and vs the US market?
Company
8.24%
Industry
11.63%
Market
3.14%
TMO's revenues are forecast to grow slower (8.24% per year) than the US Diagnostics & Research industry average (11.63%)
Forecast
TMO's revenues are forecast to grow faster (8.24% per year) than the US market average (3.14%)
Forecast
Thermo Fisher Scientific Stock Forecast FAQ
Is Thermo Fisher Scientific Stock a good buy in 2020, according to Wall Street analysts?
The consensus among 15 Wall Street analysts covering (NYSE: TMO) stock is to Strong Buy TMO stock.
Out of 15 analysts, 11 (73.33%) are recommending TMO as a Strong Buy, 2 (13.33%) are recommending TMO as a Buy, 2 (13.33%) are recommending TMO as a Hold, 0 (0.00%) are recommending TMO as a Sell, and 0 (0.00%) are recommending TMO as a Strong Sell.
What is TMO's Price Target?
According to 13 Wall Street analysts that have issued a 1 year TMO price target, the average TMO price target is $449.54, with the highest TMO stock price forecast at $494.00 and the lowest TMO stock price forecast at $340.00.
On average, Wall Street analysts predict that Thermo Fisher Scientific's share price could fall to $449.54 by Oct 8, 2021. The average Thermo Fisher Scientific stock price prediction forecasts a potential downside of 2.55% from the current TMO share price of $461.29.
What is TMO's earnings growth forecast for 2020-2022?
(NYSE: TMO) Thermo Fisher Scientific's forecast annual earnings growth rate of 36.94% is forecast to beat the US Diagnostics & Research industry's average forecast earnings growth rate of 32.45%, and and it is also forecast to beat the US market's average forecast earnings growth rate of 15.20%.
Thermo Fisher Scientific's earnings in 2020 is $3,706,000,000.On average, 9 Wall Street analysts forecast TMO's earnings for 2020 to be $6,316,571,492, with the lowest TMO earnings forecast at $6,003,256,781, and the highest TMO earnings forecast at $6,583,834,904. On average, 9 Wall Street analysts forecast TMO's earnings for 2021 to be $6,942,371,516, with the lowest TMO earnings forecast at $6,556,188,326, and the highest TMO earnings forecast at $7,504,070,976.
In 2022, TMO is forecast to generate $7,378,989,961 in earnings, with the lowest earnings forecast at $7,188,110,093 and the highest earnings forecast at $7,721,294,083.
What is TMO's revenue growth forecast for 2020-2022?
(NYSE: TMO) Thermo Fisher Scientific's forecast annual revenue growth rate of 8.24% is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 11.63%, and while it is forecast to beat the US market's average forecast revenue growth rate of 3.14%.
Thermo Fisher Scientific's revenue in 2020 is $26,248,000,000.On average, 6 Wall Street analysts forecast TMO's revenue for 2020 to be $11,507,588,024,912, with the lowest TMO revenue forecast at $11,413,786,742,761, and the highest TMO revenue forecast at $11,611,167,506,496. On average, 6 Wall Street analysts forecast TMO's revenue for 2021 to be $12,239,238,894,583, with the lowest TMO revenue forecast at $12,084,492,707,574, and the highest TMO revenue forecast at $12,459,561,972,998.
In 2022, TMO is forecast to generate $12,640,767,909,220 in revenue, with the lowest revenue forecast at $12,370,184,538,163 and the highest revenue forecast at $12,819,322,933,632.
What is TMO's Earnings Per Share (EPS) forecast for 2020-2022?
(NYSE: TMO) Thermo Fisher Scientific's current Earnings Per Share (EPS) is $9.31. On average, analysts forecast that TMO's EPS will be $15.99 for 2020, with the lowest EPS forecast at $15.20, and the highest EPS forecast at $16.67. On average, analysts forecast that TMO's EPS will be $17.58 for 2021, with the lowest EPS forecast at $16.60, and the highest EPS forecast at $19.00. In 2022, TMO's EPS is forecast to hit $18.68 (min: $18.20, max: $19.55).
What is TMO's forecast return on equity (ROE) for 2020-2022?
(NYSE: TMO) forecast ROE is 24.70%, which is considered strong.
What is TMO's forecast return on assets (ROA) for 2020-2022?
(NYSE: TMO) forecast ROA is 11.98%, which is higher than the forecast US Diagnostics & Research industry average of 10.03%.
©2020 WallStreetZen
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
